Multiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment
In spite of theoretical concerns that MP exposure during pregnancy might lead to alterations in neurodevelopment, this was not found to be the case in this cohort, with most exposures occurring during the second trimester. However, this study was not powered to detect subtle associations in secondary analyses or to draw definitive conclusions regarding potential dose-response relationships. Given the remaining uncertainties, MP should be used with caution at the lowest effective dose until larger follow-up studies provide further clarity.
Authors
- Carsten Lukas (ORCID: https://orcid.org/0000-0002-8562-9697)
- D.R. Muller (ORCID: https://orcid.org/0000-0003-3305-6767)
- Michelle Dreiling
- Hans‐Joachim Mentzel (ORCID: https://orcid.org/0000-0002-0199-3257)
- Oliver Tiedge
- Kerstin Hellwig (ORCID: https://orcid.org/0000-0003-4467-9011)
- Ruth Schneider (ORCID: https://orcid.org/0000-0002-0997-2725)
- Matthias Schwab (ORCID: https://orcid.org/0000-0002-9984-075X)
- Valeska Kozik (ORCID: https://orcid.org/0000-0002-7895-6788)
- Christian Gaser (ORCID: https://orcid.org/0000-0002-9940-099X)
- Sandra Thiel (ORCID: https://orcid.org/0000-0002-5113-8451)
- Florian Rakers (ORCID: https://orcid.org/0000-0002-3603-9711)
- Barbara Bellenberg (ORCID: https://orcid.org/0000-0001-7484-6787)
- Britta Krieger (ORCID: https://orcid.org/0000-0002-6364-2743)
Institutions
- PHV Dialysezentrum (DE)
- German Centre for Cardiovascular Research (DE)
- Jena University Hospital (DE)
- St. Josef-Hospital (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1212/wnl.0000000000214217
- Citations
- 2
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Hexal AG
- Merck KGaA
- Jazz Pharmaceuticals
- Bayer HealthCare
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Novartis Pharma
- Daiichi Sankyo Europe